These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

758 related articles for article (PubMed ID: 33166401)

  • 1. Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma.
    Facon T; Niesvizky R; Mateos MV; Siegel D; Rosenbaum C; Bringhen S; Weisel K; Ho PJ; Ludwig H; Kumar S; Wang K; Obreja M; Yang Z; Klippel Z; Mezzi K; Goldrick A; Tekle C; Dimopoulos MA
    Blood Adv; 2020 Nov; 4(21):5449-5459. PubMed ID: 33166401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-weekly (70 mg/m
    Moreau P; Stewart KA; Dimopoulos M; Siegel D; Facon T; Berenson J; Raje N; Berdeja JG; Orlowski RZ; Yang H; Ma H; Klippel Z; Zahlten-Kumeli A; Mezzi K; Iskander K; Mateos MV
    Cancer Med; 2020 May; 9(9):2989-2996. PubMed ID: 32108443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.
    Orlowski RZ; Moreau P; Niesvizky R; Ludwig H; Oriol A; Chng WJ; Goldschmidt H; Yang Z; Kimball AS; Dimopoulos M
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):522-530.e1. PubMed ID: 31160237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.
    Mateos MV; Goldschmidt H; San-Miguel J; Mikhael J; DeCosta L; Zhou L; Obreja M; Blaedel J; Szabo Z; Leleu X
    Hematol Oncol; 2018 Apr; 36(2):463-470. PubMed ID: 29446103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes.
    Hari P; Mateos MV; Abonour R; Knop S; Bensinger W; Ludwig H; Song K; Hajek R; Moreau P; Siegel DS; Feng S; Obreja M; Aggarwal SK; Iskander K; Goldschmidt H
    Leukemia; 2017 Dec; 31(12):2630-2641. PubMed ID: 28439109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR.
    Dimopoulos M; Siegel D; White DJ; Boccia R; Iskander KS; Yang Z; Kimball AS; Mezzi K; Ludwig H; Niesvizky R
    Blood; 2019 Jan; 133(2):147-155. PubMed ID: 30478094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials.
    Dimopoulos MA; Moreau P; Iida S; Huang SY; Takezako N; Chng WJ; Zahlten-Kumeli A; Sersch MA; Li J; Huang M; Lee JH
    Int J Hematol; 2019 Oct; 110(4):466-473. PubMed ID: 31388932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
    Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
    Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
    Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States.
    Kumar SK; Majer I; Panjabi S; Medhekar R; Campioni M; Dimopoulos MA
    Expert Rev Hematol; 2020 Jun; 13(6):687-696. PubMed ID: 32249621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.
    Dimopoulos MA; Coriu D; Delimpasi S; Špička I; Upchurch T; Fang B; Talpur R; Faber E; Beksac M; Leleu X
    Blood Adv; 2024 Oct; 8(19):5012-5021. PubMed ID: 39024542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
    Dimopoulos MA; Moreau P; Palumbo A; Joshua D; Pour L; Hájek R; Facon T; Ludwig H; Oriol A; Goldschmidt H; Rosiñol L; Straub J; Suvorov A; Araujo C; Rimashevskaya E; Pika T; Gaidano G; Weisel K; Goranova-Marinova V; Schwarer A; Minuk L; Masszi T; Karamanesht I; Offidani M; Hungria V; Spencer A; Orlowski RZ; Gillenwater HH; Mohamed N; Feng S; Chng WJ;
    Lancet Oncol; 2016 Jan; 17(1):27-38. PubMed ID: 26671818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China.
    Du J; Fang B; Li J; Jin J; Wang S; Zou D; Cai Z; Wang H; Hu J; Li W; Fu C; Shao Z; Xia Z; Liu P; Niu T; Tang ET; Kimball AS; Hou J; Chen W
    Int J Hematol; 2021 Mar; 113(3):422-429. PubMed ID: 33389656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials.
    Weisel K; Majer I; DeCosta L; Oriol A; Goldschmidt H; Ludwig H; Campioni M; Szabo Z; Dimopoulos M
    Leuk Lymphoma; 2020 Jan; 61(1):37-46. PubMed ID: 31640435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study.
    Dimopoulos M; Wang M; Maisnar V; Minarik J; Bensinger W; Mateos MV; Obreja M; Blaedel J; Moreau P
    J Hematol Oncol; 2018 Apr; 11(1):49. PubMed ID: 29615082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
    Mele A; Prete E; De Risi C; Citiso S; Greco G; Falcone AP; Sanpaolo G; Mele G; Giannotta A; Vergine C; Reddiconto G; Palazzo G; Sabatelli S; Germano C; Miccolis R; Curci P; Palumbo G; Offidani M; Rizzi R; Cascavilla N; Pastore D; Di Renzo N; Mazza P; Tarantini G; Guarini A; Capalbo S; Specchia G; Greco A; De Francesco R; Sibilla S; Tonialini L; Morciano MR; Pavone V
    Ann Hematol; 2021 Feb; 100(2):429-436. PubMed ID: 33161453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
    Dimopoulos M; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Yang H; Klippel Z; Zahlten-Kumeli A; Usmani SZ
    Lancet; 2020 Jul; 396(10245):186-197. PubMed ID: 32682484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy.
    Tzogani K; Camarero Jiménez J; Garcia I; Sancho-López A; Martin M; Moreau A; Demolis P; Salmonson T; Bergh J; Laane E; Ludwig H; Gisselbrecht C; Pignatti F
    Oncologist; 2017 Nov; 22(11):1339-1346. PubMed ID: 28935772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment.
    Oriol A; Dimopoulos M; Schjesvold F; Beksac M; Facon T; Dhanasiri S; Guo S; Mu Y; Hong K; Gentili C; Galli M; Yagci M; Larocca A; Richardson P; Weisel K
    Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):165-176.e4. PubMed ID: 38072743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States.
    Jakubowiak AJ; Houisse I; Májer I; Benedict Á; Campioni M; Panjabi S; Ailawadhi S
    Expert Rev Hematol; 2017 Dec; 10(12):1107-1119. PubMed ID: 29027825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.